This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Conducting a Phase Zero Study to Examine Hematologic Toxicities & Understand Dose-Limiting Effects & Mechanistic Uncertainty caused by Bystander Irradiation

Conducting a Phase Zero Study to Examine Hematologic Toxicities & Understand Dose-Limiting Effects & Mechanistic Uncertainty caused by Bystander Irradiation

11:30 am - Thursday 23rd July 2026

Characterizing early hematologic effects and dose-limiting toxicities using Phase 0 microdosing studies
Dissecting mechanisms of bystander irradiation contributing to bone marrow exposure and cytopenias
Informing dose escalation and safety margins for subsequent first-in-human and Phase 1 trials

Speakers:

Dirk Pleimes

Group Chief Executive Officer & Chief Marketing Officer

PentixaPharm GmbH